Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma

NCT06624644 is registered in ClinicalTrials.gov with Linnaeus Therapeutics, Inc. as lead sponsor.

NCT NCT06624644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06624644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma
Lead sponsor
Linnaeus Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 6, 2025
Completion date
February 28, 2031
Enrollment
135 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, melanoma (skin cancer), melanoma stage iiib-iv, unresectable melanoma